ALKS Alkermes plc

58.68
-1  -1%
Previous Close 59.43
Open 59.06
Price To book 7.49
Market Cap 8.95B
Shares 152,547,000
Volume 685,601
Short Ratio 7.24
Av. Daily Volume 848,497

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option August 8 2016. PDUFA date estimate June 8, 2017.
Aristada
Schizophrenia
Phase 3 trial to be initiated 2017 with data and NDA filing due 2018. BPC estimate of data mid-2018.
ALKS 8700
Multiple sclerosis (MS)
Phase 3 initated September 2015. Data due 1H 2017.
ALKS 6428
Opioid dependence
Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. NDA to be filed 2017.
ALKS 5461
Major depressive disorder
Approved October 5 2015. sNDA filing due 2H 2016
Aristada
Schizophrenia
Pivotal trials initiated December 2015 and February 2016. Four week efficacy data due YE 2017. Six month weight data mid-2018.
ALKS 3831 - ENLIGHTEN-1 and ENLIGHTEN-2
Schizophrenia

Latest News

  1. Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research
  2. Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research
  3. Companies Aiming for the Billion-Dollar Opioid Addiction Market
  4. Alkermes Starts Phase III Study to Treat Multiple Sclerosis
  5. Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
  6. Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
  7. Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : March 14, 2017
  8. ALKERMES PLC. Files SEC form 8-K, Other Events
  9. (video)The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
  10. The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
  11. Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference
  12. 4 Things Alkermes Wants Investors to Know
  13. Here’s What Mott Capital Management Thinks About Netflix, Alkermes, Vodafone & More
  14. Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care Conference
  15. Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care Conference
  16. Drug Addiction Treatment Stocks to Watch
  17. ALKERMES PLC. Financials
  18. Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
  19. ALKERMES PLC. Files SEC form 10-K, Annual Report
  20. Stress boom to boost drug sales?